

# Fast Forward<sup>SM</sup> Prospectus

## *Every hour of every day, someone is diagnosed with multiple sclerosis*

*For them and the millions of others worldwide living with this chronic disease, there are some drugs approved for the treatment of MS. For some people, these drugs reduce disease activity and slow the progression of the disease, but such benefits can come with significant side effects. For others, these drugs do nothing at all. And for everyone, there remains no cure for MS.*

Don't we know more about MS than ever before? Indeed. Aren't we investing millions each year into MS research? Yes — and there is no question that this investment in academic research builds a foundation of knowledge about the disease and must continue. There is also no question that we need to think differently and act boldly to make critical progress in bringing more treatment options to people with MS.

Creating a new MS therapy is both scientifically challenging and costly. This significant cost and the uncertainties associated with the drug development process have led to a situation where many promising research discoveries remain on hold, or are put aside due to the lack of funding and shared commitment to drive the development work and achieve FDA approval. At Fast Forward and the National MS Society, we know that now is the time to marshal our resources — to speed up the process — to accelerate the timetable for developing new therapies.



*We know that now  
is the time to speed the  
process — to accelerate  
the timetable for new  
therapies.*



## ***Results are needed now***

*More than 2.1 million people are affected by MS worldwide.*

Like many others with MS, Molly experiences difficulty walking as damage to nerve pathways hampers coordination and causes numbness. Fatigue sets in each afternoon, making it difficult for her to perform her job. Speech tremors make it difficult for her to communicate with colleagues and friends. For Molly, there are no treatments available as she lives with a progressive form of the disease. She yearns for more and faster progress — expanded treatment options for all forms of MS — better access to drugs — affordable and effective treatments. She sees a breakdown in the research pipeline where knowledge is abundant but therapeutic development is lagging. As a tireless champion for those with MS worldwide, Molly envisions a future with better treatments.

## ***Fast Forward — Accelerating Drug Development***

*Fast Forward, created by the National MS Society in 2007, focuses on speeding delivery of new drugs for people like Molly.*

Fast Forward funds the critical gap between promising discoveries generated by the Society's research programs and a fully facilitated commercial development process.

Fast Forward is an integral part of the National MS Society's comprehensive research program, and our joint commitment to do something about MS NOW. The Society, along with Fast Forward, is the only organization taking an end-to-end approach to MS research and treatment, actively pursuing

*Fast Forward funds the critical gap between promising discoveries generated by the Society's research programs and a fully facilitated commercial development process.*



all promising avenues to STOP the disease, RESTORE function from the damage that has already been done, and ultimately, bring an END to MS. To move us ever closer to this goal, Fast Forward provides critical funding for new ideas and promising opportunities, acts as a catalyst to connect research discoveries to development expertise and commercial capabilities, and facilitate biotechnology and pharmaceutical action, collaboration and investment.

Closing the gap between knowledge and commercially available MS treatments is what Fast Forward is all about.

## ***Creative Solutions Lead to Increased Drug Development***

*Fast Forward works to dramatically increase the number of potential drugs in the development pipeline, thereby increasing the probability of finding effective new treatments.*

Too often, promising drug treatments languish because companies lack the funding or focus to conduct pivotal research to break through the barriers, move the compound through the development pipeline, and ultimately to the clinical trials needed to develop new MS therapies. Fast Forward addresses this critical gap by providing seed money to academic groups and emerging biotechnology and pharmaceutical companies involved in drug research and development.

Fast Forward further fills the gap by creating a collaborative environment between scientists, clinicians, academic researchers and commercial visionaries. By creating these vital connections between the research, clinical trial and business communities, Fast Forward increases the focus on MS,



Carole, diagnosed in 2005

*Closing the gap  
between knowledge  
and commercially  
available MS  
treatments is what  
Fast Forward is  
all about.*





*"Thanks to Fast Forward, Amplimmune has conducted key proof-of-concept studies to understand AMP-110's unique mechanism of action and to position it on a path towards clinical development."*

-Michael Richman,  
CEO, Amplimmune



further speeding the process of bringing drugs to clinical trial. As a catalyst for collaboration, Fast Forward identifies emerging challenges, shapes research agendas and finds new opportunities for drug development in MS.

Fast Forward rigorously assesses investment opportunities by harnessing the skills of a group comprised of leading MS scientists, experienced business leaders and venture capitalists who know how to recognize promising treatment opportunities and commercialize them. This group, the Fast Forward Scientific and Business Advisory Committee, makes its funding recommendations to the Fast Forward Board of Managers, a governing body of additional individuals with scientific and business expertise, who have integrated knowledge of the Society's entire research continuum and expertise in the most effective ways to build on the successes achieved to date in MS research.

Fast Forward, through a fully-integrated approach, provides critical feedback to funded researchers and scientists, serves as mentor and guide, and prepares the end product for the next stage in drug development.

Fast Forward will be sustained by ongoing philanthropic support, collaborative funding partnerships with industry leaders as well as potential financial returns from its funding portfolio. With success comes reinvestment. Fast Forward will simultaneously fund multiple projects and may receive funding in the form of royalties or equity. Earnings will be reinvested to fund future Fast Forward initiatives.

## ***Our Shared Commitment***

*Today we know more than ever about MS, but the gap in translating that knowledge into commercialized drug therapies for people like Molly are widening.*

We have the potential to unlock tremendous resources by making an investment in today's promising innovative researchers and to help improve the lives of thousands of people living with MS. Fast Forward focuses on the critical

need for expedited drug development, leveraging the important and ongoing research discoveries generated as part of the comprehensive MS research program of the National Multiple Sclerosis Society.

## *We Need You*

Fast Forward is committed to creating a world free of MS. This commitment is undoubtedly one that we share with you. Creating change in the process required to speed treatments to market requires that all promising avenues be pursued.

The Fast Forward model is already demonstrating power in progress. In only a few years, Fast Forward has funded multiple companies and entered into a multi-year collaboration agreement with a major pharmaceutical company (EMD Serono). New partnerships are being formed, commercialization efforts are underway, promising discoveries are making their way to organizations who can develop them. The funding necessary to facilitate this progress is being provided through Fast Forward by individuals like you. Fast Forward invites you to join these bold philanthropists by making your own contribution to ensure the faster delivery of MS therapies through cutting-edge research and medical discoveries.


We need the support of people who are passionate about bringing more solutions to more people living with multiple sclerosis ... *faster*. Together we will demonstrate our mutual commitment to a thoughtful and extraordinarily innovative approach to medical discovery and drug development.

Our philanthropic partnership means accelerated drug development — for Molly, and for the people you love and care about.

To get involved today, please contact:

**Mary Milgrom**  
Executive Vice President  
Individual Giving  
303.698.6103  
800.923.7727

[www.fastforward.org](http://www.fastforward.org)



Chris, diagnosed in 1993

*Our philanthropic partnership means accelerated drug development — for Molly, and for the people you love and care about.*



Martha, diagnosed in 1973